Clinical trials
ST Elevation Myocardial Infarction trials in China with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
65 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 4 |
| 2012 | 1 |
| 2014 | 4 |
| 2015 | 8 |
| 2016 | 1 |
| 2017 | 6 |
| 2018 | 6 |
| 2019 | 8 |
| 2020 | 7 |
| 2021 | 6 |
| 2022 | 5 |
| 2023 | 3 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 65 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| RenJi Hospital | 6 |
| Xijing Hospital | 5 |
| Beijing Friendship Hospital | 4 |
| Shenzhen People's Hospital | 4 |
| Harbin Medical University | 3 |
| Peking University First Hospital | 3 |
| Beijing Anzhen Hospital | 2 |
| Beijing Chao Yang Hospital | 2 |
| Beijing Luhe Hospital | 2 |
| General Hospital of Chinese Armed Police Forces | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| ST Elevation Myocardial Infarction | 65 |
| Cardiovascular Diseases | 3 |
| Coronary Disease | 3 |
| Arterial Occlusive Diseases | 2 |
| Coronary Artery Disease | 2 |
| Heart Failure | 2 |
| Myocardial Infarction | 2 |
| Myocardial Reperfusion Injury | 2 |
| Non-ST Elevated Myocardial Infarction | 2 |
| Ventricular Remodeling | 2 |
Trials
Showing 1 to 25 of 65. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.